CSL Behring announced that the FDA has approved a 40g (400mL) vial size for Privigen (immune globulin intravenous [human] 0.1g/mL). The new vial size will reduce the required number of individual vial infusions or the need to pool multiple vials for an IV bag infusion.
Privigen is an immune globulin indicated for the treatment of chronic immune thrombocytopenic purpura (ITP) and primary immunodeficiency (eg, congenital agammaglobulinemia, X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, severe combined immunodeficiencies).
Privigen is already available in 5g (50mL), 10g (100mL), and 20g (200mL) vials. The 40g vials will be launched in June.
For more information call (888) 508-6978 or visit www.privigen.com